Tutusaus, A.; Sanduzzi-Zamparelli, M.; Boix, L.; Rider, P.; SubÃas, S.; GarcÃa de Frutos, P.; Colell, A.; MarÃ, M.; Reig, M.; Morales, A.
Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma. Cancers 2024, 16, 1491.
https://doi.org/10.3390/cancers16081491
AMA Style
Tutusaus A, Sanduzzi-Zamparelli M, Boix L, Rider P, SubÃas S, GarcÃa de Frutos P, Colell A, Marà M, Reig M, Morales A.
Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma. Cancers. 2024; 16(8):1491.
https://doi.org/10.3390/cancers16081491
Chicago/Turabian Style
Tutusaus, Anna, Marco Sanduzzi-Zamparelli, Loreto Boix, Patricia Rider, Silvia SubÃas, Pablo GarcÃa de Frutos, Anna Colell, Montserrat MarÃ, MarÃa Reig, and Albert Morales.
2024. "Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma" Cancers 16, no. 8: 1491.
https://doi.org/10.3390/cancers16081491
APA Style
Tutusaus, A., Sanduzzi-Zamparelli, M., Boix, L., Rider, P., SubÃas, S., GarcÃa de Frutos, P., Colell, A., MarÃ, M., Reig, M., & Morales, A.
(2024). Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma. Cancers, 16(8), 1491.
https://doi.org/10.3390/cancers16081491
